CJC-1295 no DAC dosing usually falls between 100 mcg and 300 mcg per injection, but this peptide is not FDA-approved. Learn typical protocols and risks.
In community and research settings, CJC-1295 no DAC dosing typically falls between 100 mcg and 300 mcg per injection, taken once or twice daily, most often before bed on an empty stomach. It is frequently stacked with a growth hormone secretagogue such as ipamorelin. CJC-1295 no DAC is not FDA-approved for human use in the United States, so everything below describes patterns reported in research literature and online forums rather than a clinical recommendation.
What Does CJC-1295 No DAC Do?
CJC-1295 no DAC is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH). So what does cjc 1295 no dac do? It binds to GHRH receptors in the pituitary gland and prompts the release of growth hormone in pulses that follow the body's natural rhythm.
The "no DAC" version lacks the drug affinity complex that extends half-life. As a result, it clears the bloodstream in roughly 30 minutes to an hour and produces a short, sharp growth hormone pulse rather than a sustained elevation.
Because the half-life is short, the no-DAC form is generally injected more often than CJC-1295 with DAC, which stays active for days.
Common CJC-1295 No DAC Dosing Ranges
Reported cjc-1295 no dac dosage varies widely depending on the source, the stated goal, and whether another peptide is stacked alongside it. A handful of patterns show up again and again in forum write-ups and vendor guides.
| Parameter | Commonly Reported Range | Notes |
|---|---|---|
| Dose per injection | 100–300 mcg | Lower end is more common in first-time protocols |
| Frequency | 1–3 times per day | Most write-ups use one or two |
| Timing | Before bed, fasted | Chosen to align with natural nighttime GH pulses |
| Cycle length | 8–12 weeks | Usually followed by a break of similar length |
| Reconstitution | 1–2 mL bacteriostatic water per vial | Concentration depends on vial size |
These figures are community conventions, not clinical standards. Most human trials of CJC-1295 studied the DAC version, and even those were small and short. No large, controlled trial has established a safe or effective dose of the no-DAC peptide.
CJC 1295 No DAC and Ipamorelin Blend
Stacking a GHRH analog with a ghrelin-mimetic is one of the most discussed combinations online. A cjc 1295 no dac and ipamorelin blend pairs two different receptor pathways, and users often describe a larger pulse than either peptide produces alone.
Pre-mixed vials typically contain 10 mg of total peptide, usually split evenly between the two compounds. Dosing is generally expressed as the combined amount per injection.
| Total Blend Dose | Approx. CJC-1295 No DAC | Approx. Ipamorelin | Typical Frequency |
|---|---|---|---|
| 100 mcg | 50 mcg | 50 mcg | 1–2 times daily |
| 200 mcg | 100 mcg | 100 mcg | 1–2 times daily |
| 300 mcg | 150 mcg | 150 mcg | Once daily |
Reconstitution math matters here. A 10 mg vial mixed with 2 mL of bacteriostatic water yields 5 mg per mL, or 5,000 mcg per mL. On a U-100 insulin syringe, that makes a 100 mcg dose a 2-unit draw.
CJC-1295 DAC vs No DAC: Which Is Better?
Asking cjc-1295 dac vs no dac which is better has no universal answer because the two versions simply behave differently. The DAC form binds to albumin and stays active for days, creating a continuous growth hormone elevation. The no-DAC form creates brief pulses that more closely resemble natural secretion.
| Feature | CJC-1295 With DAC | CJC-1295 No DAC |
|---|---|---|
| Approximate half-life | 6–8 days | 30–60 minutes |
| Injection frequency | Every 3–7 days | 1–3 times daily |
| GH release pattern | Sustained elevation | Pulsatile |
| FDA approval for human use | No | No |
Neither version is approved by the FDA, and neither has a published long-term safety record in healthy adults.
How Does CJC-1295 No DAC Compare With Tesamorelin?
In any tesamorelin vs cjc-1295 no dac comparison, the clearest difference is regulatory status. Tesamorelin (Egrifta) is FDA-approved, but only for reducing visceral fat in adults with HIV-associated lipodystrophy, at a fixed 2 mg daily subcutaneous dose.
CJC-1295 no DAC has no approved indication and is sold as a research chemical. That means purity, identity, and actual peptide content can vary substantially between vendors, and no pharmacy-level quality control applies.
Injection Timing, Storage, and Practical Notes
- Most protocols time the injection 30 to 60 minutes before sleep or at least two hours after the last meal.
- Reconstituted vials are typically stored in a refrigerator at 2–8°C and protected from light.
- Lyophilized powder that has not been mixed can be kept frozen for longer storage.
- Rotating injection sites reduces local irritation.
- Sharing vials or syringes carries a real infection risk and should never happen.
Side Effects and Safety Considerations
Reported side effects from GHRH analogs include injection-site redness, water retention, tingling or numbness in the hands, headaches, and fatigue. Some users also note changes in blood sugar or appetite.
The bigger concern is what is not known. CJC-1295 no DAC is not FDA-approved for human use, has not been tested in large randomized trials, and may carry risks that show up only with years of exposure. People with a history of cancer, pituitary disease, or diabetes should be especially cautious, because growth hormone affects cell growth and glucose metabolism.
Anyone considering this peptide should talk with a licensed healthcare professional first, and should treat forum posts as anecdotes rather than evidence.
How to Read Online Reports Critically
Personal reports describe one person's experience with an unverified product, so they cannot confirm that a peptide caused a given result.
When you read a dosing thread, check whether the poster names the vial size, the reconstitution volume, and the testing documentation. Vague reports that skip those details are difficult to interpret. A certificate of analysis from an independent lab is more informative than a screenshot of a label.
Cost is another red flag. Prices far below the market average often point to underdosed or mislabeled product.
The Bottom Line on CJC-1295 No DAC Dosing
Commonly cited CJC-1295 no DAC doses land between 100 mcg and 300 mcg per injection, one to three times daily, with 100–200 mcg before bed being the most repeated starting point. Stacked blends usually split the total dose evenly with ipamorelin.
None of these numbers come from approved labeling. CJC-1295 no DAC remains an unapproved research peptide with unknown long-term effects, and medical supervision is the only responsible way to approach any use.
Frequently Asked Questions
How much CJC-1295 no DAC do people typically take per day?
Community protocols most often cite 100 to 300 mcg per day, usually given as one or two injections timed before bed. Some users split the dose into a morning and evening injection. There is no FDA-approved human dose, and no large clinical trial has established safety or effectiveness for this peptide.
Do you have to stack CJC-1295 no DAC with ipamorelin?
No, stacking is optional. People combine them because ipamorelin acts on a different receptor pathway than CJC-1295 no DAC, and the combination is often described as producing a larger growth hormone pulse. Stacking also increases the number of unknowns, since neither peptide is FDA-approved for human use.
Is CJC-1295 no DAC legal to buy in the United States?
CJC-1295 no DAC is not FDA-approved for human use, and it is generally sold as a research chemical labeled "not for human consumption." Selling or importing it for personal human use falls into a legal gray area that varies by state. Products sold this way are not subject to pharmacy-level purity or potency testing.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.